Use of oligonucleotide telomerase inhibitors to reduce telomere length
US6194206A · kind A · utility
19Cited by
3References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 24, 1997 |
| Grant date | Feb 27, 2001 |
| Priority date | — |
| Expiry date | Dec 24, 2017 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10T436/115831
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Method and compositions are provided for the determination of telomere length and telomerase activity, as well as the ability to inhibit telomerase activity in the treatment of proliferative diseases. Particularly, primers are elongated under conditions which minimize interference from other genomic sequences, so as to obtain accurate determinations of telomeric length or telomerase activity. In addition, compositions are provided for intracellular inhibition of telomerase activity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.